DUBLIN--(BUSINESS WIRE)--The "Global mTOR (Mammalian target of rapamycin) Inhibitors Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.
The mTOR inhibitors market will register a CAGR of over 3% by 2023.
The strong prevalence of oncology indications is one of the key factors expected to trigger market growth during the forecast period. Vendors are conducting studies on target specific drugs to meet the gap between the demand and supply of these therapies. Factors including the increasing geriatric population and changes in lifestyle have also contributed to the oncology indications, in turn, contributing to the mTOR Inhibitors market growth during the forecast period.
Market Overview
Introduction of novel drug delivery systems and combination therapies
Chemotherapeutic drugs are mostly administered through conventional methods to treat different tumors. And, it is observed that the API does not reach the targeted site in appropriate quantities, thus lowering the performance of the drugs.
Adverse effects of available therapeutics
Despite being highly efficacious, mTOR inhibitors used for treating various oncology indications are associated with a spectrum of side effects. These side effects hinder patient adherence to the treatment, which poses a challenge to market growth.
Competitive Landscape
The market appears to be concentrated and with the presence of few companies including Biocon Ltd. and Intas Pharmaceuticals Ltd., the competitive environment is quite intense. Various international and national organizations are focusing on conducting programs to increase awareness about cancer and help early diagnosis of the disease. Novartis AG, Pfizer Inc., and Zydus Cadila. are some of the major companies covered in this report.
Key Topics Covered:
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
Preface
Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
Market ecosystem
Market characteristics
Market segmentation analysis
PART 04: MARKET SIZING
Market definition
Market sizing 2018
Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition
PART 06: MARKET SEGMENTATION BY ROA
Market segmentation by RoA
Comparison by RoA
Oral therapy - Market size and forecast 2018-2023
Intravenous therapy - Market size and forecast 2018-2023
Market opportunity by RoA
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
Geographic segmentation
Geographic comparison
North America - Market size and forecast 2018-2023
Europe - Market size and forecast 2018-2023
Asia - Market size and forecast 2018-2023
ROW - Market size and forecast 2018-2023
Key leading countries
Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
Market drivers
Market challenges
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
Overview
Landscape disruption
Competitive scenario
PART 13: VENDOR ANALYSIS
Vendors covered
Vendor classification
Market positioning of vendors
- Biocon Ltd.
- Intas Pharmaceuticals Ltd.
- Novartis AG
- Pfizer Inc.
-
Zydus Cadila
For more information about this report visit https://www.researchandmarkets.com/r/f5bma2
